Abelson Tyrosine Kinase Inhibitors in Parkinson's Disease and Lewy Body Dementia: A Systematic Review, Meta-analysis, and Meta-regression.
Giovanni Gosch BertonAmanda Cyntia Lima Fonseca RodriguesRafael Dos Santos BorgesNicole Rodrigues CardosoThiago Abrahão de OliveiraMarcos Vinícius Oliveira MarquesPublished in: Clinical neuropharmacology (2024)
Nilotinib (300 mg) proved effective postsensitivity analysis, unlike lower doses and bosutinib in Parkinson's disease/Lewy body dementia. Abl TKIs showed reduced efficacy in younger, more impaired patients, indicating the need for further testing with higher-potency drugs in patients who have diseases that are in the early stage but with a later onset.
Keyphrases
- end stage renal disease
- early stage
- systematic review
- newly diagnosed
- chronic kidney disease
- mild cognitive impairment
- peritoneal dialysis
- prognostic factors
- parkinson disease
- chronic myeloid leukemia
- squamous cell carcinoma
- patient reported outcomes
- tyrosine kinase
- meta analyses
- sentinel lymph node
- patient reported
- neoadjuvant chemotherapy